CPT® Code 90637

1. Indications

The quadrivalent influenza virus vaccine, as represented by CPT® Code 90637, is indicated for the prevention of influenza disease caused by the specific strains of influenza A and B viruses that are included in the vaccine formulation. This vaccine is particularly recommended for individuals who are at higher risk of developing complications from influenza, including but not limited to the following:

• High-Risk Populations: Individuals such as the elderly, young children, pregnant women, and those with chronic health conditions (e.g., asthma, diabetes, heart disease) who may experience severe illness from influenza.
• Healthcare Workers: Professionals who are in close contact with patients, especially those in high-risk categories, to help prevent the spread of influenza within healthcare settings.
• Seasonal Vaccination: General population vaccination during the flu season to reduce the overall incidence of influenza and its associated complications.

2. Procedure

The administration of the quadrivalent influenza virus vaccine involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine. Each step is critical for maintaining safety and efficacy during the vaccination process.

• Step 1: Preparation of the Vaccine The vaccine should be stored according to the manufacturer's guidelines prior to administration. Before use, the vial must be inspected for any particulate matter or discoloration. If the vaccine appears to be compromised, it should not be used. The appropriate dosage of 30 mcg per 0.5 mL is drawn into a sterile syringe, ensuring that no air bubbles are present in the syringe.
• Step 2: Patient Identification and Consent Prior to administration, the healthcare provider must verify the patient's identity and confirm that the patient is eligible for the vaccine. Informed consent should be obtained, explaining the benefits and potential risks associated with the vaccine.
• Step 3: Administration of the Vaccine The vaccine is administered via intramuscular injection, typically into the deltoid muscle of the upper arm for adults and older children, or into the anterolateral thigh for infants and young children. The injection site should be cleaned with an alcohol swab to minimize the risk of infection. The needle should be inserted at a 90-degree angle to the skin, and the vaccine should be injected slowly and steadily.
• Step 4: Post-Administration Monitoring After the vaccine is administered, the patient should be monitored for a brief period (usually 15 minutes) to observe for any immediate adverse reactions, such as allergic responses. Patients should be informed about potential side effects and advised on when to seek medical attention.

3. Post-Procedure

Following the administration of the quadrivalent influenza virus vaccine, patients may experience mild side effects, which can include soreness at the injection site, low-grade fever, or fatigue. These symptoms typically resolve within a few days. It is essential for healthcare providers to document the administration details, including the date, dosage, and site of injection, in the patient's medical record. Patients should also be advised to continue practicing preventive measures against influenza, such as hand hygiene and avoiding close contact with sick individuals, especially during flu season. Additionally, any adverse reactions should be reported according to local health regulations and guidelines.